PMC:7195088 / 10463-10932 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"172","span":{"begin":129,"end":137},"obj":"Species"},{"id":"205","span":{"begin":60,"end":71},"obj":"Chemical"},{"id":"245","span":{"begin":101,"end":109},"obj":"Disease"}],"attributes":[{"id":"A172","pred":"tao:has_database_id","subj":"172","obj":"Tax:9606"},{"id":"A205","pred":"tao:has_database_id","subj":"205","obj":"MESH:C502936"},{"id":"A245","pred":"tao:has_database_id","subj":"245","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In our opinion, this could be a reasonable off-label use of tocilizumab in these early phases of the COVID-19 pandemic, although patients and physicians should be aware that currently there is only a non–peer-reviewed, noncomparative, observational experience (very low evidence from an unreviewed cases series) and that it only supports a potential favourable effect on inflammatory signs and symptoms, while there is no information on any possible effect on survival."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T54","span":{"begin":101,"end":109},"obj":"Disease"}],"attributes":[{"id":"A54","pred":"mondo_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"In our opinion, this could be a reasonable off-label use of tocilizumab in these early phases of the COVID-19 pandemic, although patients and physicians should be aware that currently there is only a non–peer-reviewed, noncomparative, observational experience (very low evidence from an unreviewed cases series) and that it only supports a potential favourable effect on inflammatory signs and symptoms, while there is no information on any possible effect on survival."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T33","span":{"begin":30,"end":31},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T34","span":{"begin":47,"end":52},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T35","span":{"begin":198,"end":199},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T36","span":{"begin":204,"end":208},"obj":"http://purl.obolibrary.org/obo/CLO_0008416"},{"id":"T37","span":{"begin":204,"end":208},"obj":"http://purl.obolibrary.org/obo/CLO_0050081"},{"id":"T38","span":{"begin":338,"end":339},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"In our opinion, this could be a reasonable off-label use of tocilizumab in these early phases of the COVID-19 pandemic, although patients and physicians should be aware that currently there is only a non–peer-reviewed, noncomparative, observational experience (very low evidence from an unreviewed cases series) and that it only supports a potential favourable effect on inflammatory signs and symptoms, while there is no information on any possible effect on survival."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T46","span":{"begin":47,"end":52},"obj":"Chemical"},{"id":"T47","span":{"begin":60,"end":71},"obj":"Chemical"}],"attributes":[{"id":"A46","pred":"chebi_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A47","pred":"chebi_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"}],"text":"In our opinion, this could be a reasonable off-label use of tocilizumab in these early phases of the COVID-19 pandemic, although patients and physicians should be aware that currently there is only a non–peer-reviewed, noncomparative, observational experience (very low evidence from an unreviewed cases series) and that it only supports a potential favourable effect on inflammatory signs and symptoms, while there is no information on any possible effect on survival."}

{"project":"LitCovid-sentences","denotations":[{"id":"T71","span":{"begin":0,"end":469},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In our opinion, this could be a reasonable off-label use of tocilizumab in these early phases of the COVID-19 pandemic, although patients and physicians should be aware that currently there is only a non–peer-reviewed, noncomparative, observational experience (very low evidence from an unreviewed cases series) and that it only supports a potential favourable effect on inflammatory signs and symptoms, while there is no information on any possible effect on survival."}